The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Defining A Novel Mechanism Of Control Of Host Functions By Human Cytomegalovirus That Enhances Viral Pathogenesis
Funder
National Health and Medical Research Council
Funding Amount
$616,518.00
Summary
Human cytomegalovirus (HCMV) remains a significant human pathogen which causes serious and often life-threatening disease in immunosuppressed people such as bone marrow and solid organ transplant patients and in unborn babies infected during pregnancy. This project will define how HCMV controls host defences by actively modifying the cells it infects to create an environment favourable to continued viral infection and disease.
Defining A Virally-encoded Molecular Switch Between Productive And Latent Phases Of Human Cytomegalovirus Infection.
Funder
National Health and Medical Research Council
Funding Amount
$337,614.00
Summary
Human cytomegalovirus (HCMV) is a significant human pathogen which causes serious disease in immunosuppressed people such as bone marrow and solid organ transplant patients. HCMV has the capacity to switch between an active and a dormant state, enabling this virus to remain within the human host, where it can emerge years later to cause disease in immunosuppressed people. This project will define how HCMV controls the switch between active and dormant phases of infection.
Prophylactic Vaccine To Prevent Cytomegalovirus Disease
Funder
National Health and Medical Research Council
Funding Amount
$436,360.00
Summary
This project is aiming to develop a prophylactic vaccine against a common herpesvirus which has been linked to the birth defects in new born babies and significant morbidity and mortality in transplant patients. In this project we are testing a novel nanoparticle-based vaccine formulation which stimulates the immune system with single injection and the immunity induced is sustained for long-term.
The Balance Of Signals Received By NK Cells Is Modulated By Viruses As A Mean Of Immune Escape.
Funder
National Health and Medical Research Council
Funding Amount
$583,175.00
Summary
Cytomegalovirus (CMV) affects about 60% of the population in Australia. Infection is partially controlled by the immune system but CMV is never eliminated and people remain carriers for the rest of their life. Reactivation of CMV in healthy individuals is usually asymptomatic, but it causes severe diseases in people with immune deficiencies. We seek to discover the mechanisms used by CMV to escape immune surveillance, in order to gain insights into the development of improved antiviral therapies
Understanding How Cytomegaloviruses Establish Systemic Infection
Funder
National Health and Medical Research Council
Funding Amount
$668,144.00
Summary
Human cytomegalovirus (HCMV) infects most Australians, causes birth defects and harms transplant patients. Vaccines against it have worked poorly. HCMV spreads throughout the body and is never cleared. To control infection we must identify its key checkpoints. Using mouse CMV, we find that host dendritic cells, which normally defend against infections, are taken over and spread virus to new sites. The viral gene responsible is a potential target for intervention. We will define how it works.
What Is The Profile, Burden And Consequences Of Cerebral Palsy (CP) Due To Congenital Cytomegalovirus (CMV) Infection?
Funder
National Health and Medical Research Council
Funding Amount
$87,130.00
Summary
Cytomegalovirus (CMV) is a virus that can be transmitted from mother to the unborn child. It is a potentially preventable cause of cerebral palsy (CP). The incidence of CP due to CMV remains unclear in Australia as screening for CMV is not routinely performed in the newborn. Our preliminary data suggests that severe CP is strongly associated with CMV. Here we will use link recorded data and test CMV in newborn screening cards to determine the burden and profile of CP due to congenital CMV in Aus ....Cytomegalovirus (CMV) is a virus that can be transmitted from mother to the unborn child. It is a potentially preventable cause of cerebral palsy (CP). The incidence of CP due to CMV remains unclear in Australia as screening for CMV is not routinely performed in the newborn. Our preliminary data suggests that severe CP is strongly associated with CMV. Here we will use link recorded data and test CMV in newborn screening cards to determine the burden and profile of CP due to congenital CMV in Australia.Read moreRead less
Human Cytomegalovirus Encoded Control Of The Latent Phase Of Infection
Funder
National Health and Medical Research Council
Funding Amount
$639,871.00
Summary
Human cytomegalovirus has the ability to hide in the body of a person throughout their life time without it making them ill but the virus can awaken (reactivate) from this latent state and produce new virus. In immunosuppressed people such as transplant patients this reactivation causes significant problems, even death, yet this latency remains poorly understood. This project will help us to understand how the virus can hide successfully from the immune system in a latent form in the human host.
Whole-of-population CRISPR Point-of-care Testing For Congenital Cytomegalovirus To Prevent Hearing And Neurodevelopment Disabilities Through A Public Health Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,058,920.00
Summary
Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.
Viral infections that mothers catch during pregnancy still cause much illness in babies either in the womb, or after birth. One of these infections called CMV causes more babies to be born with malformation in Australia than any other infection, and is second only to cerebral palsy as a cause of serious problems in babies. Our studies are examining CMV in mothers and babies, leading to better diagnostic tests, researching use of existing and new antiviral drugs to reduce infection in these mothe ....Viral infections that mothers catch during pregnancy still cause much illness in babies either in the womb, or after birth. One of these infections called CMV causes more babies to be born with malformation in Australia than any other infection, and is second only to cerebral palsy as a cause of serious problems in babies. Our studies are examining CMV in mothers and babies, leading to better diagnostic tests, researching use of existing and new antiviral drugs to reduce infection in these mothers and babies.Read moreRead less
Improving Treatment And Outcomes Of Congenital Hearing Loss At The Population Level
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
Around 600 Australian babies are born with congenital hearing loss each year. Despite great advances in early diagnosis and treatment, affected children have language and other skills well below what they can potentially achieve. My research will a) examine trends in congenital hearing loss outcomes, b) enrich existing data with novel genetic and clinical data, to enable early prediction of future outcomes to direct management, and c) discover ways to prevent hearing loss progression.